 |
|
| • |
|
| • |
|
| • |
|
| • |
|
|
| • |
|
| • |
|
| • |
|
| • |
|
| • |
|
|
| • |
|
| • |
|
| • |
|
| • |
|
| • |
|
| • |
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
Div. of Media Relations
1600 Clifton Road
MS D-14
Atlanta, GA 30333
(404) 639-3286
Fax (404) 639-7394 |
|
|
|
 |
Synopsis for November 17, 2000
MMWR articles are embargoed until 4 p.m. E.S.T.
Thursdays.
- Public Health Consequences Among First Responders
to Emergency Events Associated With Illicit Methamphetamine
Laboratories — Selected States, 1996–1999
- Progress Toward Poliomyelitis Eradication —
Eastern Mediterranean Region, 1999–September 2000
Recommendations & Reports
Vol. 49 (RR-13) November 17, 2000
Use of Diphtheria Toxoid-Tetanus Toxoid-Acellular Pertussis Vaccine
as a Five-Dose Series: Supplemental Recommendations of the Advisory
Committee on Immunization Practices (ACIP)
Four vaccines containing diphtheria and tetanus toxoids and acellular
pertussis vaccine (DTaP) are currently licensed in the United States for
use among infants and young children. As of October 2000, two products
were licensed for the five-dose DTaP vaccination series. Two other
vaccines ) are licensed for the first four doses of the vaccination
series, beginning with the primary series at ages 2, 4, and 6 months, and
for completing the DTaP series among children who began the series with
diphtheria and tetanus toxoids and whole-cell pertussis vaccine. This
report supplements the statement from CDC's ACIP regarding use of
acellular pertussis vaccines and summarizes data regarding reactogenicity
of acellular pertussis vaccines when administered as the fourth and fifth
consecutive doses. Increases in the frequency and magnitude of local
reactions at the injection site with increasing dose number have occurred
for all currently licensed DTaP vaccines. Because data are insufficient
regarding the safety, immunogenicity, and efficacy of using DTaP vaccines
from different manufacturers in a mixed sequence, ACIP continues to
recommend that, whenever feasible, the same brand of DTaP vaccine be used
for all doses in the vaccination series. When the vaccine provider does
not know or does not have available the type of DTaP vaccine previously
administered, any of the licensed DTaP vaccines can be used to complete
the vaccine series.
Contact: Lynn Zanardi, M.D.
CDC, National Immunization Program
(404) 639–8253
Synopsis for November 17, 2000
Public Health Consequences Among First Responders to
Emergency Events Associated With Illicit Methamphetamine Laboratories —
Selected States, 1996–1999
Hazardous substances released from active or
abandoned methamphetamine laboratories have the potential to cause serious
injury and death, specifically among first responders.
PRESS CONTACT:
D. Kevin Horton, M.S.P.H.
Agency for Toxic Substances & Disease Registry, CDC
(404) 639–6203
|
|
Hazardous substances released from active or abandoned methamphetamine
laboratories have the potential to cause serious injury and death. The
Agency for Toxic Substances and Disease Registry, CDC maintains the
Hazardous Substances Emergency Events Surveillance system to collect and
analyze information about the morbidity and mortality associated with
hazardous substance events in 16 participating states. An event is defined
as an uncontrolled or illegal release or threatened release of a hazardous
substance(s). Findings from 1996-1999 data indicate that, of the
methamphetamine laboratory events, the highest number of injured persons
were first responders (i.e., police officers, firefighters). This report
describes those injuries to first responders, summarizes events that
involved injured first responders, and suggests injury prevention methods
to protect first responders.
Progress Toward Poliomyelitis Eradication — Eastern Mediterranean
Region, 1999–September 2000
It appears by the end of 2000, poliovirus
transmission will be eliminated in 19 of the 23 EMR countries.
PRESS CONTACT:
Victor M. Caceres, M.D., M.P.H.
CDC, National Immunization Program
(404) 639–8252 |
|
In 1988 the Regional Committee for the Eastern Mediterranean Region (EMR)
of the World Health Organization (WHO) resolved to eradicate poliomyelitis
from the region 2000. Since then, there has been remarkable progress
surveillance and implementation of coordinated National Immunization Days
(NIDs). During 1999-2000, the quality of NIDs improved substantially
through house to house vaccination. Also during this period, all but 4
countries achieved surveillance quality indicators indicative of sensitive
surveillance, while the number of confirmed polio cases has decreased by
approximately 50%. Remaining challenges include reaching children in
countries with armed conflict, intensifying program activities in
remaining endemic countries, and reaching and maintaining high routine OPV
coverage high to prevent spreading of imported polioviruses.
|
